Mode
Text Size
Log in / Sign up

Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis15,000 Cases Found: Which Drugs Harm Your Lungs?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note positive associations between five medications and drug-induced eosinophilic pneumonia in pharmacovigilance data.

This retrospective pharmacovigilance investigation utilized FAERS and Vigibase databases to examine individuals with drug-induced eosinophilic pneumonia. The analysis identified 15,374 cases in total within the FAERS database to assess adverse reactions associated with specific drug exposures. No comparator was reported in the study design. Primary outcomes included detection of adverse reactions associated with drug-related EP.

Highest incidence occurred among individuals aged 45 to 64 years, accounting for 24.1% of cases. Hospitalization was required for 35.4% of affected patients. Drug-specific odds ratios indicated positive associations for daptomycin (OR 12.50, 95% CI 9.40–16.75), durvalumab (OR 5.17, 95% CI 3.74–7.14), fam-trastuzumab deruxtecan (OR 4.86, 95% CI 3.32–7.04), idelalisib (OR 4.74, 95% CI 3.13–7.07), and osimertinib (OR 3.21, 95% CI 2.11–4.79). Secondary outcomes also assessed hospitalization rate and time-to-onset.

This real-world data mining study observed that observational design limits causal inference, and signal detection requires confirmation. Database mining is subject to reporting bias. Follow-up duration was not reported. Adverse events included eosinophilic pneumonia, with 35.4% requiring hospitalization. Early discontinuation of offending drug, timely initiation of corticosteroid therapy, and multidisciplinary collaboration are fundamental to achieving improved outcomes.

  • 15,374 cases linked to medicines causing lung inflammation.
  • Cancer and infection drugs show the highest risk.
  • Doctors need to watch for early warning signs.

A massive data review reveals which medicines might silently damage your lungs.

Imagine taking a pill to fight a serious infection. Days later, you struggle to breathe. This sounds scary, but it happens.

Eosinophilic pneumonia is a rare lung issue. It happens when white blood cells pile up in the lungs. Doctors often miss it at first.

Many people take strong medicines for cancer or infections. These drugs save lives. But sometimes, they cause side effects. We need to know which ones.

Why This Is a Big Deal

Experts knew some drugs could hurt lungs. But they did not know the full picture. This new study changes that view.

We used to rely on small reports. Now we have data from thousands of patients. This gives us a clearer map.

The Surprising Data Shift

Think of your immune system like a security guard. Usually, it protects you. Sometimes, medicine confuses the guard.

It attacks the lungs instead. This causes swelling and trouble breathing. It is like a fire alarm going off in an empty room.

The body sends too many white blood cells to the wrong place. They get stuck and cause damage.

How Your Body Reacts

The study checked real-world data from 2026. They tracked 15,374 cases. Most patients were between 45 and 64 years old.

Researchers looked at two big databases. One was from the US. The other was global. They found many links.

The Numbers Behind the News

Nivolumab and pembrolizumab were top on the list. These are cancer treatments. Daptomycin was also high. This is an antibiotic.

Daptomycin had the strongest link. It was 12 times more likely to cause the issue. Other drugs were 3 to 5 times more likely.

About 35 percent of patients needed the hospital. This shows the condition can get serious fast.

Most cases happened early after starting the drug. This means you must watch closely at first.

Which Drugs Are Risky?

But there is a catch. Just because a drug is on the list does not mean you will get sick. Most people take these safely.

Doctors say stopping the drug early helps. Steroids can reduce swelling in the lungs. A team of doctors should manage this.

They need to work together to fix the problem. Time is very important for recovery.

What Doctors Recommend

Do not stop your medicine on your own. Talk to your doctor if you feel short of breath. They know your history best.

Some people take many medicines at once. This raises the risk slightly. You should review your list with a pharmacist.

Weight and age also play a role. Older adults need closer monitoring.

If you have a cough or fever, speak up. Do not wait for it to get worse.

The Limits of This Study

This data comes from reports. It is not a controlled experiment. Some links might be coincidental. We need more proof.

Doctors might report side effects more often. This can make a drug look worse than it is. We must be careful.

The study looked at past data only. It did not test new patients.

Scientists will keep watching these drugs. Better tools will help spot risks sooner. Your safety is the main goal.

Future studies will test these findings. We hope to prevent this before it starts.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundEosinophilic pneumonia (EP) is an uncommon, idiopathic interstitial lung disease distinguished by the atypical accumulation of eosinophils within the pulmonary parenchyma and airways. The condition often presents insidiously and is frequently overlooked or misdiagnosed; pharmacological agents are among the acknowledged precipitants of this disorder.MethodsThis is a retrospective pharmacovigilance investigation. We utilized the FAERS and Vigibase databases to detect adverse reactions associated with drug-related EP.ResultsWe identified a total of 15,374 cases of drug-induced EP in FAERS. The incidence was highest, at 24.1%, among individuals aged 45 to 64 years, with 35.4% of the affected patients requiring hospitalization. In terms of the numerical composition of PTs, pneumonitis was the most predominant PT. Although the proportion of PTs varied for each drug and pneumonitis remained the most common, antibacterials exhibited a higher prevalence of “eosinophilic pneumonia” and “pulmonary eosinophilia.” Notable observations include significant signal variations between the two databases for certain drugs, yet all positive signal drugs identified by FAERS can be confirmed by Vigibase. Initial screening identified 302 suspect drugs; following disproportionality filtering, univariate analysis, and lasso shrinkage, 56 agents were retained. Nivolumab was the most frequently reported drug (1,377 reports), followed by pembrolizumab (1,070 reports) and daptomycin (758 reports), with daptomycin exhibiting the most significant statistical signal in FAERS. Time-to-onset analysis indicated that EP typically manifested early. Multivariable modeling identified higher body weight, advancing age, and polypharmacy as associated factors. The drugs most strongly associated with EP were daptomycin (OR 12.50, 95% CI 9.40–16.75), durvalumab (OR 5.17, 95% CI 3.74–7.14), fam-trastuzumab deruxtecan (OR 4.86, 95% CI 3.32–7.04), idelalisib (OR 4.74, 95% CI 3.13–7.07), and osimertinib (OR 3.21, 95% CI 2.11–4.79).ConclusionThe early discontinuation of the offending drug, timely initiation of corticosteroid therapy, and multidisciplinary collaboration are fundamental to achieving improved outcomes in cases of drug-induced eosinophilic pneumonia. This study offers substantial real-world evidence to facilitate the early identification and optimal management of eosinophilic pneumonia.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.